Intellectual Property
(Non-confidential)

City of Hope
NATIONAL MEDICAL CENTER AND
BECKMAN RESEARCH INSTITUTE

Treating Liposarcomas Using HIV Protease Inhibitors



DESCRIPTION

Liposarcoma is the second most common adult soft tissue sarcoma, accounting for approximately 20% of all sarcomas. Sarcomas consist of a heterogeneous group of histologically distinct malignancies that arise from mesenchymal tissues. Liposarcomas are malignant tumors derived from primitive or embryonal lipoblastic cells and are histologically distinct from Kaposi's sarcoma, an indolent vascular tumor. Metastatic liposarcoma is associated with an extremely poor prognosis, with average 5-year survivals ranging from 70% to as low as 25% depending on the makeup of the tumor. This technology covers the use of HIV protease inhibitors such as **Nelfinavir** for the treatment of Liposarcomas. These protease inhibitors selectively inhibit liposarcoma clonogenicity.

KEY ASPECTS

- The protease inhibitors that can be used to treat Liposarcomas include Nelfinavir, Indinavir and Ritonavir
- This protease inhibitor treatment may be used in conjunction with standard chemotherapy and surgical resection of the sarcoma

PUBLISHED DATA

- Anti-HIV drugs for cancer therapeutics: back to the future? *The Lancet Oncology*, Volume 10, Issue 1, Pages 61-71 W. Chow, C. Jiang, M. Guan
- *Journal of Clinical Oncology*, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010: e13538
- Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1, *Anti-Cancer Drugs*: September 2006 - Volume 17 - Issue 8 - pp 891-90, W. Chow

INTELLECTUAL PROPERTY

Title	US Patent Number	Issued
Method of Using Protease Inhibitors for the Treatment of Liposarcomas	7,812,034	10/12/2010

CONTACT

Matthew Grunseth, M.B.S.
Manager, Office of Technology Licensing
Telephone: (626) 471-7221 | Email: mgrunseth@coh.org